Precision Medicine Companion Diagnostic (CDx)
To precisely treat cancer patients, we partnered with Roche to develop a companion diagnostic (CDx). Preliminary data indicates that 70% of breast cancers express activated RSK2 including metastases.
More broadly, an investigation of 600 biopsies revealed that RSK2 is activated in 79% of tumors from a study of 14 different tumor types. In our Phase 2 clinical trial, we will enroll patients who have high levels of RSK2 using our CDx assay.
Together, our drug and CDx have the potential to improve outcomes for patients by accelerating their path to treatment.